Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mutation Abnormality Clear all
Terminated Not applicable Interventional Results available

Recombinant Human Chorionic Gonadotropin in Preventing Breast Cancer in Premenopausal Women With BRCA1 Mutations

NCT00700778
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer
Interventions
recombinant human chorionic gonadotropin, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis, needle biopsy
Biological · Genetic · Other + 1 more
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 12, 2026, 11:32 AM EDT
Recruiting No phase listed Observational

Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

NCT06311708
View directory record Official record
Conditions
Arrhythmogenic Right Ventricular Cardiomyopathy
Interventions
Not listed
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
14 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Results available

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

NCT01531673
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661, Ivacaftor, Placebo matched to VX-661, Placebo matched to ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Oakland, California • Boise, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 1 Interventional

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients

NCT02388594
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
ZFN Modified CD4+ T Cells, Cyclophosphamide
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

NCT01037127
View directory record Official record
Conditions
Cancer
Interventions
GSK1120212
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 12, 2026, 11:32 AM EDT
Withdrawn Early Phase 1 Interventional

Multimodality MRI and Liquid Biopsy in GBM

NCT04776980
View directory record Official record
Conditions
Glioblastoma Multiforme, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Recurrent, Brain Tumor, Primary
Interventions
Post Feraheme Infusion MRI
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Results available

Study of Ataluren in ≥2 to <5 Year-Old Male Participants With Duchenne Muscular Dystrophy

NCT02819557
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
2 Years to 5 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Gulf Breeze, Florida • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 12, 2026, 11:32 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Growth Hormone in a Patient With a Dominant-Negative GHR Mutation

NCT05382637
View directory record Official record
Conditions
Growth Disorders
Interventions
Somatropin
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
9 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

NCT01086267
View directory record Official record
Conditions
Colorectal Cancer
Interventions
BMS-908662, Cetuximab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Sep 12, 2026, 11:32 AM EDT
Recruiting Not applicable Interventional

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

NCT06972719
View directory record Official record
Conditions
BRCA1 Mutation, BRCA2 Mutation
Interventions
Experimental Arm, SOC Arm
Behavioral
Lead sponsor
Duke University
Other
Eligibility
19 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 2 Interventional

An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer

NCT00580112
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Dexamethasone, Trabectedin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
21
States / cities
Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2014 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

NCT02347657
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 Plus Ivacaftor Combination, Ivacaftor, VX-661 Plus Ivacaftor Combination Placebo, Ivacaftor placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Little Rock, Arkansas • Long Beach, California • Denver, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 2Phase 3 Interventional Results available

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
Afatinib Dimaleate, Cetuximab, Laboratory Biomarker Analysis
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
638
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 12, 2026, 11:32 AM EDT
Active, not recruiting No phase listed Observational

INHERIT EGFR - Studying Germline EGFR Mutations

NCT01754025
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

NCT05054374
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
Interventions
Mirdametinib, Fulvestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 2 Interventional Results available

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

NCT04056910
View directory record Official record
Conditions
Advanced Solid Tumor, IDH1 Mutation, Glioma
Interventions
ivosidenib and nivolumab
Drug
Lead sponsor
Jason J. Luke, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 12, 2026, 11:32 AM EDT
Active, not recruiting Phase 2 Interventional

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

NCT04061980
View directory record Official record
Conditions
BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
Interventions
Binimetinib, Encorafenib, Nivolumab
Drug · Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 1 Interventional Results available

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

NCT01264380
View directory record Official record
Conditions
Malignant Melanoma
Interventions
RO5185426
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 12, 2026, 11:32 AM EDT
Recruiting Phase 1 Interventional

Combination Therapy in Cancers With Mutations in DNA Repair Genes

NCT05694715
View directory record Official record
Conditions
Metastatic Solid Tumor, BRCA1 Mutation, BRCA2 Mutation, ATM Gene Mutation, PALB2 Gene Mutation
Interventions
Niraparib, Irinotecan
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 12, 2026, 11:32 AM EDT
Recruiting Early Phase 1 Interventional

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

NCT06610682
View directory record Official record
Conditions
BRAF V600E Mutation
Interventions
Plixorafenib, Retifanlimab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

NCT02252146
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
IMO-8400
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Decatur, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Sep 12, 2026, 11:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Osimertinib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
15
States / cities
Anchorage, Alaska • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 12, 2026, 11:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

NCT06501625
View directory record Official record
Conditions
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Interventions
Ivosidenib, Durvalumab (for the first 8, 21-day, cycles), Gemcitabine (for the first 8, 21-day, cycles), Cisplatin (for the first 8, 21-day, cycles), Durvalumab (starting from cycle 9), Ivosidenib Recommended Combination Dose (RCD)
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Los Alamitos, California • Los Angeles, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 12, 2026, 11:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

NCT02565914
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 12, 2026, 11:32 AM EDT